The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

USPTO Grants Composition of Matter Patent to Achillion

23-Mar-2017 | Source : Achillion Pharmaceuticals | Visits : 4807
NEW HAVEN, Conn. - Achillion Pharmaceuticals Inc. announced in a press release that the US Patent and Trademark Office (USPTO) has issued the first US Patent to Achillion resulting from its complement factor D research program.

US Patent No. 9,598,446 has been granted with claims to compositions of matter for compounds that inhibit complement factor D activity, a key mediator in the complement alternative pathway (AP). In addition, the USPTO has issued Notices of Allowance of four additional US patent applications owned by Achillion, also with claims to compositions of matter, that are expected to issue as patents over the next few months.

"Achillion's aim is to establish a broad patent portfolio for its complement program. With the granting of this first patent we are pleased that the USPTO has confirmed that Achillion possesses a multitude of patentable complement factor D inhibitors," commented Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion. "As a leader in AP biology, we are proud to have been the first to clinically demonstrate, in healthy volunteers, the ability to suppress AP activity following oral dosing of our complement factor D inhibitor, ACH-4471. The receipt of this patent, along with a number of additional patent applications under review by the USPTO, strengthens our position as a leader in factor D inhibitors for the potential treatment of AP-mediated diseases, such as C3G, PNH and geographic atrophy."

Achillion Pharmaceuticals Inc. is a science-driven, patient-focused company seeking to leverage its strengths across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases. 

Related Articles